依那普利与氯沙坦在高血压患者中的降压效果与安全性对比研究  

A Comparative Study on the Antihypertensive Effect and Safety of Enalapril and Losartan in Patients with Hypertension

作　　者：陈润丽 CHEN Runli(The Sixth People's Hospital of Nanning,Nanning,Guangxi 530003)

机构地区：[1]南宁市第六人民医院,广西南宁530003

出　　处：《智慧健康》2025年第3期123-126,共4页Smart Healthcare

摘　　要：目的探讨依那普利与氯沙坦在高血压患者中的降压效果及安全性差异,为临床用药选择提供依据。方法选取2023年1月—2024年1月本医疗机构诊治的80例高血压患者,随机分为对照组(依那普利,n=40)和实验组(氯沙坦,n=40)。对比两组患者的降压效果(收缩压和舒张压)、肾功能指标变化[24 h尿蛋白(UPE)、血清肌酐(SCr)、内生肌酐清除率(CCr)]及安全性(不良反应发生率)。结果治疗前,两组患者的收缩压(SBP)和舒张压(DBP)差异无统计学意义(P>0.05);治疗后,两组患者的SBP和DBP均较治疗前显著下降(P<0.05),但实验组的降压效果显著优于对照组(P<0.05)。治疗前,两组患者的24 h尿蛋白(UPE)、血清肌酐(SCr)、内生肌酐清除率(CCr)差异无统计学意义(P>0.05);治疗后,两组患者的肾功能指标均较治疗前有所改善,且实验组改善幅度显著优于对照组(P<0.05)。实验组患者治疗期间的不良反应发生率明显低于对照组(P<0.05)。结论氯沙坦在高血压患者中较依那普利具有更好的降压效果和安全性,值得临床推广。Objective To investigate the antihypertensive effects and safety differences between enalapril and losartan in patients with hypertension,and to provide evidence for clinical drug selection.Methods A total of 80 hypertensive patients diagnosed and treated in our hospital from January 2023 to January 2024 were randomly divided into control group(enalapril,n=40)and experimental group(losartan,n=40).The antihypertensive effect(systolic and diastolic blood pressure),renal function indicators[24-hour urinary protein(UPE),serum creatinine(SCr),endogenous creatinine clearance(CCr)]and safety(incidence of adverse reactions)were compared between the two groups.Results Before treatment,there was no significant difference in systolic blood pressure(SBP)and diastolic blood pressure(DBP)between 2 groups(P>0.05).After treatment,SBP and DBP of both groups were significantly decreased compared with that before treatment(P<0.05),but the antihypertensive effect of the experimental group was significantly better than that of the control group(P<0.05).Before treatment,there were no significant differences in 24-hour urinary protein(UPE),serum creatinine(SCr)and endogenous creatinine clearance(CCr)between 2 groups(P>0.05).After treatment,renal function indexes of both groups were improved compared with those before treatment,and the improvement range of the experimental group was significantly better than that of the control group(P<0.05).The incidence of adverse reactions in the experimental group was significantly lower than that in the control group(P<0.05).Conclusion Losartan has better antihypertensive effect and safety than enalapril in patients with hypertension,which is worthy of clinical promotion.

关 键 词：依那普利 氯沙坦 高血压 降压效果 

分 类 号：R544.1[医药卫生—心血管疾病]